Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain

Leichsenring, Anna; Andriske, Michael; Bäcker, Ingo; Stichel, Christine C.; Lübbert, Hermann

doi:10.1007/s00210-008-0386-4

Cited by 36 publications

(26 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute WIN55,212-2 suppresses all forms of neuropathic nociception tested in this model. Chronic administration of WIN55,212-2 also attenuates the development of mechanical allodynia and suppresses glial activation in the spinal cord following SNL with no overt motor side-effects 81. Chronic administration of WIN55,212-2 produced anti-allodynic effects up to six days following the final injection.…”

Section: Cannabinoid Modulation Of Neuropathic Nociception In Animal mentioning

confidence: 87%

Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside

2009

View full text Add to dashboard Cite

Summary:Neuropathic pain is a debilitating form of chronic pain resulting from nerve injury, disease states, or toxic insults. Neuropathic pain is often refractory to conventional pharmacotherapies, necessitating validation of novel analgesics. Cannabinoids, drugs that share the same target as ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC), the psychoactive ingredient in cannabis, have the potential to address this unmet need. Here, we review studies evaluating cannabinoids for neuropathic pain management in the clinical and preclinical literature. Neuropathic pain associated with nerve injury, diabetes, chemotherapeutic treatment, human immunodeficiency virus, multiple sclerosis, and herpes zoster infection is considered. In animals, cannabinoids attenuate neuropathic nociception produced by traumatic nerve injury, disease, and toxic insults. Effects of mixed cannabinoid CB 1 /CB 2 agonists, CB 2 selective agonists, and modulators of the endocannabinoid system (i.e., inhibitors of transport or degradation) are compared. Effects of genetic disruption of cannabinoid receptors or enzymes controlling endocannabinoid degradation on neuropathic nociception are described. Specific forms of allodynia and hyperalgesia modulated by cannabinoids are also considered. In humans, effects of smoked marijuana, synthetic ⌬ 9 -THC analogs (e.g., Marinol, Cesamet) and medicinal cannabis preparations containing both ⌬ 9 -THC and cannabidiol (e.g., Sativex, Cannador) in neuropathic pain states are reviewed. Clinical studies largely affirm that neuropathic pain patients derive benefits from cannabinoid treatment. Subjective (i.e., rating scales) and objective (i.e., stimulusevoked) measures of pain and quality of life are considered. Finally, limitations of cannabinoid pharmacotherapies are discussed together with directions for future research.

show abstract

Section: Cannabinoid Modulation Of Neuropathic Nociception In Animal mentioning

confidence: 87%

Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside

2009

View full text Add to dashboard Cite

show abstract

“…It has been used in several animal studies to investigate the anti-inflammatory and anti-nociceptive characteristics of CB 2 R agonists [107][108][109]. In a rat neuropathic pain model, GW405833 showed inhibitory effects on the formation of gliosis and inhibited neuropathic pain [110]. GW405833 was recently described as being a protean agonist [111].…”

Section: Indole Derivativesmentioning

confidence: 99%

Non-Invasive Imaging of the Type 2 Cannabinoid Receptor, Focus on Positron Emission Tomography

Evens¹,

Bormans²

2010

CTMC

View full text Add to dashboard Cite

The type 2 cannabinoid receptor (CB 2 R) is a relatively new target for drug development, as the receptor was only discovered in 1993. The CB 2 R is mainly expressed in tissues and organs related to the immune system. However, in pathological conditions, mostly inflammatory, a strong upregulation has been observed. Because of its expression in activated microglia, the type 2 cannabinoid receptor might play an important role in pathologies with a neuroinflammatory component. Positron emission tomography provides a sensitive non-invasive imaging technique to study and quantify receptor expression. In this review, the importance of CB 2 R imaging, the current status and the future possibilities for the development of CB 2 R PET radioligands are discussed.

show abstract

“…administration of JWH-015 [96] or i.p. administration of GW405833 [170], a partial CB 2 R agonist. Taken together, these reports demonstrate that CB 2 R agonists are able to alter spinal glial activation states and create in vivo anti-inflammatory effects suitable for pain control.…”

Section: Well-characterized Cb2r Synthetic Compoundsmentioning

confidence: 99%

“…injection of GW405833 was able to provide sustained reversal from allodynia following SNL. That is, animals did not develop tolerance to this compound, which was in stark contrast to treatment with the mixed CB 1 R/CB 2 R agonist WIN55,212-22 [170]. Additionally, allodynia returned after intermittent treatment of GW405833.…”

Section: Well-characterized Cb2r Synthetic Compoundsmentioning

confidence: 99%

The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief

Wilkerson

Milligan

2011

ISRN Anesthesiology

View full text Add to dashboard Cite

Under normal conditions, acute pain processing consists of well-characterized neuronal signaling events. When dysfunctional pain signaling occurs, pathological pain ensues. Glial activation and their released factors participate in the mediation of pathological pain. The use of cannabinoid compounds for pain relief is currently an area of great interest for both basic scientists and physicians. These compounds, bind mainly either the cannabinoid receptor subtype 1 (CB1R) or cannabinoid receptor subtype 2 (CB2R) and are able to modulate pain. Although cannabinoids were initially only thought to modulate pain via neuronal mechanisms within the central nervous system, strong evidence now supports that CB2R cannabinoid compounds are capable of modulating glia, (e.g. astrocytes and microglia) for pain relief. However, the mechanisms underlying cannabinoid receptor-mediated pain relief remain largely unknown. An emerging body of evidence supports that CB2R agonist compounds may prove to be powerful novel therapeutic candidates for the treatment of chronic pain.

show abstract

Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain

Cited by 36 publications

References 54 publications

Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside

Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside

Non-Invasive Imaging of the Type 2 Cannabinoid Receptor, Focus on Positron Emission Tomography

The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief

Contact Info

Product

Resources

About